Portal de Periódicos da CAPES

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety

2021; Adis, Springer Healthcare; Volume: 44; Issue: 12 Linguagem: Inglês

10.1007/s40264-021-01131-6

1179-1942

Nicoletta Luxi, Alexia Giovanazzi, Annalisa Capuano, Salvatore Crisafulli, Paola Maria Cutroneo, Maria Pia Fantini, Carmen Ferrajolo, Ugo Moretti, Elisabetta Poluzzi, Emanuel Raschi, Claudia Ravaldi, Chiara Reno, Marco Tuccori, Alfredo Vannacci, Giovanna Zanoni, Gianluca Trifirò, Gianluca Trifirò, Ugo Moretti, Nicoletta Luxi, Alexia Giovanazzi, Giuliana Petrelli, Silvia Girotti, Elena Arzenton, Lara Magro, Riccardo Lora, David Bellantuono, Alberto Sabaini, Alberto Firenze, Donatella Zodda, Fabrizia Guidotti, Maria Zappone, Bernardo Alagna, Edoardo Spina, Paola Maria Cutroneo, Claudia Minore, Claudio Costantino, Arianna Conforto, Francesco Vitale, Ilaria Morreale, Laura Marsala, Desirè Farinella, Silvana Bavetta, Emanuel Raschi, Elisabetta Poluzzi, Maria Pia Fantini, Chiara Reno, Ester Sapigni, Anna Maria Potenza, Debora Podetti, Victoria Nikitina, Rita Ricciardelli, Nazanin Mogheiseh, Silvia Croce, Barbara Paltrinieri, Sofia Castellani, Elisa Sangiorgi, Margherita Selleri, Simona Lucchesi, Giuseppe Catucci, Denis Savini, Chiara Sacripanti, Marco Faccioli, Maria Silvia Romio, Laura Rossi, Simonetta Radici, Giovanna Negri, Lidia Fares, Chiara Ajolfi, Antonella Fadda, Antonella Chiarello, Fabio Pieraccini, Francesco Pappalardo, Marco Tuccori, Alfredo Vannacci, Roberto Bonaiuti, Claudia Ravaldi, Niccolò Lombardi, Giada Crescioli, Roberto Tessari, Emanuela Zandonà, Francesco Marchiori, Cristiano Chiamulera, Giovanna Zanoni, Gianenrico Senna, Mariangiola Crivellaro, Mauro Cancian, Francesca Venturini, Marina Ferri, Luca Leonardi, Sabrina Orzetti, Elisabetta Caccin, Paolo Baldo, Annalisa Capuano, Concetta Rafaniello, Carmen Ferrajolo, Claudia Pagliaro, Mariangela Mercaldo, Annamaria Fucile, Annalisa Di Giorgio, Michele Tari, Sonia Manna, Giuseppina Farina, Cristina Di Mauro, Ilenia De Carlo, Ilenia Senesi, Claudia Pileggi, Caterina Palleria, Luca Gallelli, Caterina De Sarro, Luigia Trabace, Mariagrazia Morgese, Stefania Schiavone, Paolo Tucci, María Bové, Francesco Lapi, Claudio Cricelli, Giorgio Racagni, Silvia Tonolo, Eugenio Leopardi, Giusi Fava, Sandro Giuffrida, Vincenza Amato, Marco Gambera, Valentina Montresor,

SARS-CoV-2 and COVID-19 Research

To date, four vaccines have been authorised for emergency use and under conditional approval by the European Medicines Agency to prevent COVID-19: Comirnaty, COVID-19 Vaccine Janssen, Spikevax (previously COVID-19 Vaccine Moderna) and Vaxzevria (previously COVID-19 Vaccine AstraZeneca). Although the benefit–risk profile of these vaccines was proven to be largely favourable in the general population, evidence in special cohorts initially excluded from the pivotal trials, such as pregnant and breastfeeding women, children/adolescents, immunocompromised people and persons with a history of allergy or previous SARS-CoV-2 infection, is still limited. In this narrative review, we critically overview pre- and post-marketing evidence on the potential benefits and risks of marketed COVID-19 vaccines in the above-mentioned special cohorts. In addition, we summarise the recommendations of the scientific societies and regulatory agencies about COVID-19 primary prevention in the same vaccinee categories.